Compare Genuine Parts Company (GPC) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Heron Therapeutics Inc — how do they compare? Genuine Parts Company trades at $127.56 (market cap $17.29B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Genuine Parts Company is far larger — about 233.5× Heron Therapeutics Inc's market cap, and Genuine Parts Company pays a 3.39% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Heron Therapeutics Inc for 35 Days on average.
| GPC | HRTX | |
|---|---|---|
Market Cap | $17.29B | $74.04M |
Volume | 900,870 | 3,668,095 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $1.49 |
52-Week Low | $92.47 | $0.27 |
Typical Hold Time | 75 Days | 35 Days |
Enterprise Value | $23.38B | $180.78M |
Dividend Yield | 3.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 0.62% today, with a bearish technical signal but neutral oscillators. The company reported mixed earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a Buy with a $145.75 price target, and the upcoming spinoff of the industrial unit Motion in Q1 2027 is a key catalyst.
The outlook is cautiously optimistic due to the spinoff potential and dividend stability, but risks include declining profitability, high P/E ratio of 501.64, and bearish technical trends. Investors should weigh the long-term benefits of the separation against near-term margin pressures and debt levels rising to 23.08% of assets in 2025.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
